Associated Papers
Targeting HER2 genomic alterations in non-small cell lung cancer.
Zeng J et al.
Journal of the National Cancer Center, 2021
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.
Shin JW et al.
Biomolecules, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
31034466 (PubMed )
Supplement: pcbi.1006981.s010.xlsx › final_benchmark
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J et al.
The Oncologist, 2015
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Greulich H et al.
Proceedings of the National Academy of Sciences of the United States of America, 2012
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Unknown Author
Nature, 2008
Select a paper to view details